Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 28;16(3):2789–2796. doi: 10.3892/ol.2018.9036

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Sun et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Therapeutic effect of rAAV-endostatin in RCC tumor. (A) The therapeutic model. (B) A total of 10 days following OR-SC-2 inoculation, intratumoral rAAV-endostatin (1.0×10¹¹ v.p) or control virus injections into the established tumor were performed. The xenograft tumors with rAAV-endostatin injection took longer to reach 300 mm³ compared with the control groups: rAAV-Endostatin group, 32.63±9.75 days; rAAV-EYFP group, 21.75±10.48 days; RPMI-1640 group, 21.50±11.42 days. (C) Hematoxylin and eosin staining of the OS-RC-2 kidney tumor at magnification, ×200. Representative images from three independent experiments were presented. (D) Subsequent to harvesting the xenograft (kidney) tumors, specimens were paraffin-embedded and cut into 5-µm thick sections and processed for immunohistochemical staining of factor VIII-associated antigen. The brown areas indicate microvascular structures (magnification, ×200). Representative images from three independent experiments were shown. rAAV, recombinant adenovirus-associated vector; EYFP, enhanced yellow florescent protein.